PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form	1449/PTO			Complete if Known		
				·	Application Number	10/049,871	
ट्य	INFO	PRMATION	N DISCLOS	URE	Filing Date	October 3, 2003	
	STA	TEMENT I	BY APPLIC	ANT	First Named Inventor	Yanina Rozenberg et al.	
ab Joet Breet	(Use as many sheets as necessary)				Art Unit	1632	
DE1					Examiner Name	To Be Assigned	
Street		1	of	2	Attorney Docket Number	38147-0039 (271010-473)	

1			U.S. PATENT DO	CUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.'	Number-Kind Code ²	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
-Dr	1.	US-5,631,018	05-20-1997	Zalipsky et al.	·
	2.	US-5,661,022	08-26-1997	Kotani et al.	
	3.	US-5,665,577	09-09-1997	Sodroski et al.	
	4.	US-5,686,279	11-11-1997	Finer et al.	
	5.	US-5,766,625	06-16-1998	Schreier et al.	
5	6.	US-5,780,221	07-14-1998	Schumacher et al.	
	7.	US-5,916,803	06-29-1999	Sedlacek et al.	
	8.		•		·
	9.				
	10.				

		FC	DREIGN PATEN'	T DOCUMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code*Number*Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
-70	ノ I.	WO 91/19798	12-26-1991	Sodroski et al.		
1	2.	WO 97/12622	04-10-1997	Verma et al.		
	3.	WO 97/40854	11-06-1997	Summerton et al.		
(4.	WO 98/12314	03-26-1998	Trono et al.		
	5.					
	6.	·				
	7.	•				
	8.	•				
	9.					

Examiner	()mi	1.3-10	Date	(Marila)
Signature	-/00	Wallace	Considered	4/25/06

*Examiner: Initial referedce considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Su	bstitut	e for form	1449/PTO			Complete if Known		
TPE	1	>					Application Number	10/049,871	
Ø'' ~	4	37	INFORMATION DISCLOSURE				Filing Date	October 3, 2003	
		, <u>"</u>	STATEMENT BY APPLICANT			ANT	First Named Inventor	Yanina Rozenberg et al.	
JUN 2 5	700	, Pic		(Use as many sheets as necessary)			Art Unit	1632	
		<i>'0</i> \	<u></u>				Examiner Name	To Be Assigned	
TAY.	3	89et		2	of	2	Attorney Docket Number	38147-0039 (271010-473)	
& TRA	كرون			-					

		NON-PATENT LITERATURE DOCUMENTS	
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	T ⁶
Initials*	No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher,	ļ
		city and/or country where published.	
	1.	ANDERSON, Nature, 392 (6679 Suppl): 25-30 (1998).	
$\frac{2}{3}$		BOUSSIF et al., Proc. Natl. Acad. Sci. USA, 92:7297-7301 (1995).	
-+-		BOXUS et al., Bioorganic and Medicinal Chemistry, 6:1577-1595 (1998).	
	4.	CHOI et al., Bioconjugate Chem., 9:708-718 (1998).	ļ
	5.	FASBENDER et al., J. Biol. Chem., 272:6479-6489 (1997).	
	6.	HAUBNER et al., Angew. Chem. Int. Ed. Engl., 36:1374-1389 (1997).	<u> </u>
	7.	KAGAWA et al., J. Biol. Chem., 246, 17:5477-5487 (1971).	ļ
	8.	KIEBER-EMMONS et al., Current Opinion in Biotechnology, 8:432-441 (1997).	
	9.	KIRPOTIN et al., FEBS Letters, 388:115-118 (1996).	<u> </u>
	10.	KWOH et al., Biochimica et Biophysica Acta, 1444:171-190 (1999).	
	111.	MEYER et al., FEBS Letters, 421:61-64 (1998).	
	12.	MEYER et al., J. Biol. Chem., 372, 25:15621-15627 (1998).	
	13.	MINOURA, Langmuir, 14:2145-2147 (1998).	
	14.	NAKANISHI et al., J. of Controlled Release 54:61-68 (1998).	ļ
	15.	PAPAHADJOPOULOS et al., Proc. Natl. Acad. Sci. USA, 15: 11460-4 (1991).	
	16.	PAPISOV, Adv. Drug Delivery Review, 32:119-138 (1998).	
	17.	PAULETTI et al., Adv. Drug Delivery Review, 27:235-256 (1997).	
	18.	SAPHIRE et al., J. Biol. Chem., 273, 45:29764-29769 (1998).	
	19.	SCHNIERLE AND GRONER, Gene Therapy, 3:1069-73 (1996).	
	20.	SUBBARAO et al., Biochemistry, 26:2964-2972 (1987).	
	21.	TANG et al., Biochem. Biophys. Res. Comm., 242:141-145 (1998).	
	22.	VERMA et al., Nature, 389: 239-42 (1997).	
	23.	VIEWEG et al., Cancer Research, 55: 2366-2372 (1995).	i –
	24.	VINOGRADOV et al., Bioconjugate Chem., 9:805-812 (1998).	i
	25.	WOODLE et al., "Small Molecule Ligands for Targeting Long Circulating Liposomes",	
[-	Long Circulating Liposomes: Old Drugs, New Therapeutics, pp. 287-295, Ed. by	
		Woodle and Storm, Springer-Verlag and Landes Bioscence (1998).	[
	26.	WYMAN et al., Biochemistry, 36:3008-3017 (1997).	†
1	27.	ZANTA et al., Proc. Natl. Acad. Sci. USA, 96:91-96 (1999).	<u> </u>
_	28.	ZELPHATI et al., Gene Therapy, 5:1272-1282 (1998).	

Examiner			Date	1 / /	_
Signature	<u></u>	O(1-) (1-)	Considered	10/29/06	

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute fo	or form 1449/PTO	W.	ARRIV	Complete if Known		
		RA	DEMAL	Application Number	10/049,871	
I	NFORMATIO	N DISCLOS	URE	Filing Date	October 3, 2003	
	STATEMENT 1	BY APPLIC	ANT	First Named Inventor	Yanina Rozenberg et al.	
	(Use as many sl	neets as necessary)		Art Unit	1632	
				Examiner Name	To Be Assigned	
Sheet	1	of	1	Attorney Docket Number	38147-0039	

		NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T°
7	1.	HONG, et al., Chinese Medical Journal, 108(5): 332-337, 1995.	
	2.	HUANG, Biochemistry, Vol. 8, No. 1, pp. 344-351 (1969).	
	3.	MARUYAMA, et al., Biochimica et Biophysica Acta, 1234, pp. 74-80, (1995).	
5	4.	SCHOEPFER, et al., Bioorganic & Medicinal Chemistry Letters, Vol. 8, pp. 2865-2870 (1998).	
7	5.	SZOKA, et al., Biochimica et Biophysica Acta, 601, pp. 559-571 (1980).	
5	6.	TORCHILIN, et al., Journal of Pharmaceutical Sciences, Vol. 84, No. 9, pp. 1049 - 1053 (1995).	
7	7.	USTER et al., FEBS Letters, 386:243-246 (1996).	
7	8.	ZALIPSKY, et al., Journal of Pharmaceutical Sciences, Vol. 85, No. 2, pp. 133-137 (1996).	
		·	
			<u> </u>
			ļ
		·	
			<u> </u>
			
ŀ			i

Examiner			Date	. / /
Signature	100	(land)	Considered	10/29/04

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.